X

Drug Profile

Research programme: protein tyrosine phosphatase inhibitors - CEPTYR

Alternative Names: CPT 633

Latest Information Update: 04 Feb 2011

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CEPTYR
Developer CEPTYR; Eli Lilly
Class
Mechanism of Action Protein tyrosine phosphatase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Type 2 diabetes mellitus

Most Recent Events

04 Feb 2011 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
29 May 2006 A preclinical study with the selected compound CPT 633 has been added to the Type-2 diabetes pharmacodynamics section
11 Jul 2003 The programme is available for licensing (http://www.ceptyr.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com